FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246750892> ?p ?o ?g. }

• W4246750892 abstract "Abstract Background: Informative serum biomarkers for monitoring inflammatory activity and treatment responses in axial spondyloarthritis (axSpA) are lacking. We assessed whether Lipocalin 2 (LCN2) and Oncostatin M (OSM), both have roles in inflammation and bone remodeling, may accurately reflect chronic inflammation and treatment response in axSpA. Previous reports in animal models showed involvement of LCN2 and OSM in gut inflammation. We asked whether they also play a role in human axSpA. Methods. A nalysis of a longitudinal observational axSpA cohort (286 patients) with yearly clinical assessments and concurrent measurements of serum LCN2 and OSM (1204 serum samples) for up to 12 years. Biomarkers levels were correlated with MRI scoring and treatment response. Results. Persistent and transient elevation of LCN2 and OSM were observed in axSpA patients. Persistent elevation of LCN2 or OSM, but not CRP, was correlated with sacroiliac joint MRI SPARCC scores (Pearson’s correlation p = 0.0005 and 0.005 for LCN2 and OSM respectively). We observed both concordant and discordant patterns of LCN2 and OSM in relationship to back pain, the cardinal clinical symptom in axSpA. 26% (73/286) of the patients remained both clinically and serologically active (CASA). 14% (40/286) of them remained clinically active with back pain, but were serologically quiescent (CASQ). 60% (173/286) of the patients became clinically quiescent, with back pain resolved, but 53% (92/173) of them were serologically active (CQSA). With respect to treatment responses, transient elevation of LCN2 or OSM over time was predictive of better response to all treatments. The data suggest that failure to normalize LCN2 and OSM indicates persistent chronic inflammation, as reflected by positive MRI imaging of the sacroiliac joints. Prevalence of severe ankyloses is comparable in CQSA and CASA patients, indicating that disease progresses even when back pain may be controlled (CQ) Conclusion . In axSpA, persistent LCN2 and/or OSM elevation reflects chronic SIJ inflammation and suboptimal treatment response. In our cohort, half of the currently deemed clinically quiescent patients with back pain resolved, continued to demonstrate chronic inflammation. LCN2 and OSM profiling outperforms CRP as a predictive measure and provides an objective assessment of chronic local inflammation in axSpA patients." @default.
• W4246750892 created "2022-05-12" @default.
• W4246750892 creator A5000255317 @default.
• W4246750892 creator A5012163630 @default.
• W4246750892 creator A5030858951 @default.
• W4246750892 creator A5031379810 @default.
• W4246750892 creator A5038121079 @default.
• W4246750892 creator A5078476681 @default.
• W4246750892 date "2021-02-11" @default.
• W4246750892 modified "2023-10-16" @default.
• W4246750892 title "Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis" @default.
• W4246750892 doi "https://doi.org/10.21203/rs.3.rs-194998/v1" @default.
• W4246750892 hasPublicationYear "2021" @default.
• W4246750892 type Work @default.
• W4246750892 citedByCount "0" @default.
• W4246750892 crossrefType "posted-content" @default.
• W4246750892 hasAuthorship W4246750892A5000255317 @default.
• W4246750892 hasAuthorship W4246750892A5012163630 @default.
• W4246750892 hasAuthorship W4246750892A5030858951 @default.
• W4246750892 hasAuthorship W4246750892A5031379810 @default.
• W4246750892 hasAuthorship W4246750892A5038121079 @default.
• W4246750892 hasAuthorship W4246750892A5078476681 @default.
• W4246750892 hasBestOaLocation W42467508921 @default.
• W4246750892 hasConcept C11988809 @default.
• W4246750892 hasConcept C126322002 @default.
• W4246750892 hasConcept C20299238 @default.
• W4246750892 hasConcept C2776213234 @default.
• W4246750892 hasConcept C2776914184 @default.
• W4246750892 hasConcept C2777402515 @default.
• W4246750892 hasConcept C2777667943 @default.
• W4246750892 hasConcept C2778579456 @default.
• W4246750892 hasConcept C71924100 @default.
• W4246750892 hasConcept C72563966 @default.
• W4246750892 hasConcept C90924648 @default.
• W4246750892 hasConceptScore W4246750892C11988809 @default.
• W4246750892 hasConceptScore W4246750892C126322002 @default.
• W4246750892 hasConceptScore W4246750892C20299238 @default.
• W4246750892 hasConceptScore W4246750892C2776213234 @default.
• W4246750892 hasConceptScore W4246750892C2776914184 @default.
• W4246750892 hasConceptScore W4246750892C2777402515 @default.
• W4246750892 hasConceptScore W4246750892C2777667943 @default.
• W4246750892 hasConceptScore W4246750892C2778579456 @default.
• W4246750892 hasConceptScore W4246750892C71924100 @default.
• W4246750892 hasConceptScore W4246750892C72563966 @default.
• W4246750892 hasConceptScore W4246750892C90924648 @default.
• W4246750892 hasLocation W42467508921 @default.
• W4246750892 hasOpenAccess W4246750892 @default.
• W4246750892 hasPrimaryLocation W42467508921 @default.
• W4246750892 hasRelatedWork W1367695 @default.
• W4246750892 hasRelatedWork W14000303 @default.
• W4246750892 hasRelatedWork W14204453 @default.
• W4246750892 hasRelatedWork W14644975 @default.
• W4246750892 hasRelatedWork W14957554 @default.
• W4246750892 hasRelatedWork W15228753 @default.
• W4246750892 hasRelatedWork W15539055 @default.
• W4246750892 hasRelatedWork W327577 @default.
• W4246750892 hasRelatedWork W483946 @default.
• W4246750892 hasRelatedWork W8834189 @default.
• W4246750892 isParatext "false" @default.
• W4246750892 isRetracted "false" @default.
• W4246750892 workType "article" @default.